Seward B. Rutkove

Seward B. Rutkove

Auto-generated profile, based on publicly available information

Seward B. Rutkove

Department of Neurology, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
SKStephen J. Kolb
Stephen J. Kolb
CCChristopher S. Coffey
Christopher S. Coffey
JYJon W. Yankey
Jon W. Yankey
KKKristin J. Krosschell
Kristin J. Krosschell
WAWilliam david Arnold
William david Arnold
TIthe NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators
the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators

18 September 2009 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
SRSeward B. Rutkove
Seward B. Rutkove

3 August 2012 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
MCMatteo Cesari
Matteo Cesari
RFRoger Fielding
Roger Fielding
MPMarco Pahor
Marco Pahor
BGBret Goodpaster
Bret Goodpaster
MHMarc Hellerstein
Marc Hellerstein
BVBruno Vellas
Bruno Vellas
Sarcopenia, the age‐related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7–8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging‐related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age‐related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.

13 March 2012 in Stem Cells
Verified
Journal Article
Open access
PDF file
JGJonathan D. Glass
Jonathan D. Glass
NBNicholas M. Boulis
Nicholas M. Boulis
KJKarl Johe
Karl Johe
SRSeward B. Rutkove
Seward B. Rutkove
TFThais Federici
Thais Federici
EFEva L. Feldman
Eva L. Feldman
Advances in stem cell biology have generated intense interest in the prospect of transplanting stem cells into the nervous system for the treatment of neurodegenerative diseases. Here, we report the results of an ongoing phase I trial of intraspinal injections of fetal-derived neural stems cells in patients with amyotrophic lateral sclerosis (ALS). This is a first-in-human clinical trial with the goal of assessing the safety and tolerability of the surgical procedure, the introduction of stem cells into the spinal cord, and the use of immunosuppressant drugs in this patient population. Twelve patients received either five unilateral or five bilateral (10 total) injections into the lumbar spinal cord at a dose of 100,000 cells per injection. All patients tolerated the treatment without any long-term complications related to either the surgical procedure or the implantation of stem cells. Clinical assessments ranging from 6 to 18 months after transplantation demonstrated no evidence of acceleration of disease progression due to the intervention. One patient has shown improvement in his clinical status, although these data must be interpreted with caution since this trial was neither designed nor powered to measure treatment efficacy. These results allow us to report success in achieving the phase I goal of demonstrating safety of this therapeutic approach. Based on these positive results, we can now advance this trial by testing intraspinal injections into the cervical spinal cord, with the goal of protecting motor neuron pools affecting respiratory function, which may prolong life for patients with ALS. STEM CELLS2012;30:1144–1151

1 September 2019 in Clinical Neurophysiology
Verified
Journal Article
Open access
ESErik Stålberg
Erik Stålberg
HDHans van Dijk
Hans van Dijk
BFBjörn Falck
Björn Falck
JKJun Kimura
Jun Kimura
CNChristoph Neuwirth
Christoph Neuwirth
MZMachiel Zwarts
Machiel Zwarts
This document is an update and extension of ICCN Standards published in 1999. It is the consensus of experts on the current status of EMG and Neurography methods. A panel of authors from different countries with different approach to routines in neurophysiological methods was chosen based on their particular interest and previous publications. Each member of the panel submitted a section on their particular area of interest and these submissions were circulated among the panel members for edits and comments. This process continued until a consensus was reached. The document covers EMG topics such as conventional EMG, Macro EMG, applications of surface EMG and electrical impedance myography. Single Fiber EMG is not included, since it is the topic in a separate IFCN document. A neurography section covers topics such as motor and sensory neurography, F wave recordings, H-reflex, short segment recordings, CMAP scan and motor unit number methods. Other sections cover repetitive nerve stimulation and Pediatric electrodiagnostic testing. Each method includes a description of methodologies, pitfalls, and the use of reference values. Clinical applications accompany some of these sections.

7 March 2014 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
EFEva L. Feldman
Eva L. Feldman
NBNicholas M. Boulis
Nicholas M. Boulis
Junguk HurJunguk Hur
Junguk Hur
KJKarl Johe
Karl Johe
SRSeward B. Rutkove
Seward B. Rutkove
JGJonathan D. Glass
Jonathan D. Glass
Objective: The US Food and Drug Administration–approved trial, “A Phase 1, Open‐Label, First‐in‐Human, Feasibility and Safety Study of Human Spinal Cord‐Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis, Protocol Number: NS2008‐1,” is complete. Our overall objective was to assess the safety and feasibility of stem cell transplantation into lumbar and/or cervical spinal cord regions in amyotrophic lateral sclerosis (ALS) subjects.Methods: Preliminary results have been reported on the initial trial cohort of 12 ALS subjects. Here, we describe the safety and functional outcome monitoring results for the final trial cohort, consisting of 6 ALS subjects receiving 5 unilateral cervical intraspinal neural stem cell injections. Three of these subjects previously received 10 total bilateral lumbar injections as part of the earlier trial cohort. All injections utilized a novel spinal‐mounted stabilization and injection device to deliver 100,000 neural stem cells per injection, for a dosing range up to 1.5 million cells. Subject assessments included detailed pre‐ and postsurgical neurological outcome measures.Results: The cervical injection procedure was well tolerated and disease progression did not accelerate in any subject, verifying the safety and feasibility of cervical and dual‐targeting approaches. Analyses on outcome data revealed preliminary insight into potential windows of stem cell biological activity and identified clinical assessment measures that closely correlate with ALS Functional Rating Scale‐Revised scores, a standard assessment for ALS clinical trials.Interpretation: This is the first report of cervical and dual‐targeted intraspinal transplantation of neural stem cells in ALS subjects. This approach is feasible and well‐tolerated, supporting future trial phases examining therapeutic dosing and efficacy. Ann Neurol 2014;75:363–373